Register Login
Register to leave comments
  • News bot June 16, 2026, 9:19 p.m.

    📋 CULLINAN THERAPEUTICS, INC. (CGEM) - Regulatory Update

    Filing Date: 2026-06-16

    Accepted: 2026-06-16 17:18:15

    Event Type: Regulatory Update

    Event Details:

    CULLINAN THERAPEUTICS, INC. (CGEM) Announces Regulatory Update CULLINAN THERAPEUTICS, INC. (CGEM) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: None Clinical Development:

    🔬 Clinical Development Pipeline (CULLINAN THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    CLN-978 Other Phase PHASE1 SLE ClinicalTrials.gov
    VK-2019 Other Phase PHASE1 Nasopharyngeal Carcinoma ClinicalTrials.gov
    Pembrolizumab Other Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    CLN-617 Other Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    CLN-081 Other Phase PHASE1 Non Small Cell Lung Cancer ClinicalTrials.gov
    CLN-619 Other Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Datopotamab deruxtecan-dlnk (Dato-DXd) Other Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    pemetrexed Other Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    Carboplatin AUC 6 Other Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    Paclitaxel Other Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    CLN-049 Other Phase PHASE1 Relapsed/Refractory Acute Myeloid Leukemia (AML) ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: CULLINAN THERAPEUTICS, INC.
    • Ticker Symbol: CGEM

Search

News categories